Robert M. Lorence

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

Vincent A. Miller, Vera Hirsh, Jacques Cadranel et al. · The Lancet Oncology · 2012 · 950 citations

Oncology, Phase 2B/3, Afatinib Versus Placebo +9

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

James Chih‐Hsin Yang, Jin‐Yuan Shih, Wu‐Chou Su et al. · The Lancet Oncology · 2012 · 402 citations

Advanced Lung Disease, Medicine, Lung Adenocarcinoma +10

Phase I Trial of Intravenous Administration of PV701, an Oncolytic Virus, in Patients With Advanced Solid Cancers

Andrew L. Pecora, Naiyer A. Rizvi, Gary I. Cohen et al. · Journal of Clinical Oncology · 2002 · 386 citations

Newcastle disease virus selectively kills human tumor cells

Kirk W. Reichard, Robert M. Lorence, Christopher J. Cascino et al. · Journal of Surgical Research · 1992 · 244 citations

Viral Pathogenesis, Pathology, Virology +4

LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.

James Chih‐Hsin Yang, Martin Schüler, Nobuyuki Yamamoto et al. · Journal of Clinical Oncology · 2012 · 171 citations

Surgical Oncology, Cancer Management, Pathology +17